Clinical data | |
---|---|
Trade names | Turalio |
Other names | PLX-3397 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619050 |
License data |
|
Routes of administration | By mouth |
Drug class | Kinase inhibitor[1] |
Legal status | |
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C20H15ClF3N5 |
Molar mass | 417.82 g·mol−1 |
3D model (JSmol) | |
| |
|
Pexidartinib, sold under the brand name Turalio, is a medication used to treat tenosynovial giant cell tumor (TGCT).[1] It is used in cases which result in significant problems and cannot be treated by surgery.[1] It is taken by mouth.[1]
Common side effects include liver problems, loss of hair color, tiredness, low neutrophils, increased cholesterol, eye swelling, and rash.[2] The liver problems can result in death.[2] Use in pregnancy may harm the baby.[1] It is a kinase inhibitor and works by blocking colony-stimulating factor-1 receptor (CSF-1R).[1]
Pexidartinib was approved for medical use in the United States in 2019.[1] It was refused approval in Europe in 2020 due to minimal benefits and concerns regarding side effects.[3] It is not approved in the United Kingdom.[4] In the United States it costs about 21,200 USD per month.[5]
References
edit- ^ a b c d e f g h "Pexidartinib Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 27 October 2021.
- ^ a b c "DailyMed - TURALIO- pexidartinib capsule". dailymed.nlm.nih.gov. Archived from the original on 24 October 2020. Retrieved 27 October 2021.
- ^ "Turalio". Archived from the original on 27 October 2021. Retrieved 27 October 2021.
- ^ "Pexidartinib". SPS - Specialist Pharmacy Service. 12 January 2016. Archived from the original on 27 October 2021. Retrieved 27 October 2021.
- ^ "Turalio Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 27 October 2021.